Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Content
    • Current Issue
    • Complete Issue PDF
    • Archive
    • Collections
    • Blog
  • Multimedia
    • Audio
    • Pediatrics On Call Podcast
  • CME/MOC
    • CME Quizzes
    • MOC Claiming
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Content
    • Current Issue
    • Complete Issue PDF
    • Archive
    • Collections
    • Blog
  • Multimedia
    • Audio
    • Pediatrics On Call Podcast
  • CME/MOC
    • CME Quizzes
    • MOC Claiming
  • Subscribe
  • Alerts
  • Careers
American Academy of Pediatrics
Adolescent Medicine

Isotretinoin and Pregnancy-Related Adverse Events

AAP Grand Rounds October 2019, 42 (4) 40; DOI: https://doi.org/10.1542/gr.42-4-40
Quiz
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Source: Tkachenko E, Singer S, Sharma P, et al. US Food and Drug Administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin. JAMA Dermatol. 2019 17 July [published online ahead of print]; doi: 10.1001/jamadermatol.2019.1388OpenUrlCrossRef

Investigators from multiple institutions conducted a retrospective analysis of reports made to the US Food and Drug Administration (FDA) to assess the rates of pregnancy-related adverse events associated with isotretinoin use before and after the 2006 implementation of the iPLEDGE program. iPLEDGE was meant to reduce fetal exposure to isotretinoin by requiring female patients of childbearing potential to have a negative pregnancy test and verify 2 forms of contraception monthly to obtain an isotretinoin prescription. iPLEDGE also requires prescribers to report to the FDA any pregnancies among isotretinoin users.

Investigators used the FDA …

View Full Text

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

AAP Grand Rounds
Vol. 42, Issue 4
1 Oct 2019
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Isotretinoin and Pregnancy-Related Adverse Events
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Isotretinoin and Pregnancy-Related Adverse Events
AAP Grand Rounds Oct 2019, 42 (4) 40; DOI: 10.1542/gr.42-4-40

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Quiz
Share
Isotretinoin and Pregnancy-Related Adverse Events
AAP Grand Rounds Oct 2019, 42 (4) 40; DOI: 10.1542/gr.42-4-40
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents
  • Current Issue
  • Past Issues
  • Collections
  • Editorial Board
  • Overview
  • CME Quizzes
  • MOC Claiming

Jump to section

  • Article
    • Bottom Line
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments

Related Articles

  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Liraglutide for Weight Reduction in Obese Adolescents
  • Sleep Restriction and Memory and Learning in Adolescents
  • Oral HPV and Vaccination Among Female Adolescents
Show more Adolescent Medicine

Similar Articles

  • Journal Info
  • Editorial Board
  • Overview
  • Licensing Information
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • shopAAP
  • AAP.org
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics